Malaria Diagnosis: Current Approaches and

Future Prospects by Onile-ere, Olabode et al.
	Malaria Diagnosis: Current Approaches and 
Future Prospects 
Onile-ere Olabode, Openibo John and Olasehinde Grace 
Department of Biological Sciences, 
Covenant University, 
Ota, Nigeria 
 
Abstract- Scaled up efforts by a consortia of organisations in 
the diagnosis, treatment and prevention of malaria have led to a 
significant reduction in the overall malaria mortality and 
morbidity in the past few years. Malaria has, nonetheless, 
remained one of the world’s most burdensome diseases with the 
over 214 million cases and 438,000 deaths recorded in 2015 
(2.68% of global DALYs). This burden is unevenly domiciled in 
sub-Saharan Africa where 89% of all cases and 91% of all deaths 
occurred. These figures however, only represent a fraction of the 
actual global burden of Malaria as surveillance fails to cover 
most cases in sub-Saharan Africa where the majority of malaria 
endemic regions lack facilities for diagnosis, case management 
and active surveillance. The emergence of drug resistant strains 
of the Plasmodium species prompted WHO to recommend a 
confirmatory diagnosis of each case of Malaria before treatment. 
The workability of this recommendation however, begs to be 
questioned as the majority of all malaria diagnosis is done via 
Clinical diagnosis; which lacks precision, is still the major form 
of diagnosis in many malaria endemic regions, and contributes to 
the over-diagnosis of malaria and subsequent under-diagnosis of 
other febrile illnesses. Of higher import is the risk of the 
emergence of drug resistant species due to the unregulated 
antimalarial use caused by inaccurate clinical diagnosis. 
Microscopy, which is the gold standard of malaria diagnosis, and 
the Rapid Diagnostic Tests (RDT) for malaria antigens have 
proven to be very useful in the diagnosis of malaria giving high 
levels of specificity and sensitivity. They however have the 
downside of having relatively high limits of detection, 
invasiveness, being labour intensive and expensive in the light of 
the low income countries where malaria is endemic. More 
sophisticated tools such as those that employ nucleic acid 
techniques (Polymerase Chain Reaction and Gene probes) are 
not field deployable and are mostly applied for research 
purposes. This necessitates the need for new diagnostic 
approaches that are suited to the conditions found in malaria 
endemic regions. A range of novel diagnostic tools with a do-it-
yourself approach, leveraging on previously untapped diagnostic 
material such as urine are currently being assessed. These novel 
tools promise great results if successful. This review presents an 
overview of current diagnostic methods, the prospects in malaria 
diagnostics and finally makes an effort to recommend what an 
ideal malaria diagnostic tool should be made up of, all the while 
focusing on sub-Saharan Africa. 
Keywords- Malaria, Diagnosis, sub-Saharan Africa 
 
 
I. INTRODUCTION 
The end of the Millennium Development Goals (MDGs) 
necessitated the switch to Sustainable Development Goals 
(SDGs). A great deal of progress was made during the 15 
years ofMDGs as it relates to malaria. The world saw a 37% 
and 60% reduction in malaria incidence and mortality with 
increased coverage of key interventions such as Insecticide 
Treated Nets, preventive treatment in pregnancy and increased 
use of rapid diagnostic tests[1], there is however a great deal 
of work to be done as there are still many issues threatening 
the new goal of eradicating malaria by 2030.  
The WHO in its recent strategy forelimination has 
identified malaria diagnosis as a major factor in getting to zero 
come 2030 as prompt and accurate diagnosis is the mainstay 
for effective disease management and surveillance[2]. 
Currently, malaria diagnosis rests majorly on the Microscopic 
detection of parasites and Rapid Diagnostic tests (RDT)[3]. 
These two tools have proven really effective in times past but 
may fall short in playing their role towards malaria 
elimination viz-a-viz their shortcomings.  
A. Objectives 
This review considered the status of currently used 
diagnostic methods as well as prospective tools in delivering 
the information which will help inform policy in a bid to 
eliminating malaria in sub Saharan Africa where the bulk of 
the burden lies. 
B. Methods 
In this review, keywords such as ‘malaria’, ‘diagnosis’, 
‘issues’ and ‘prospects’ were put into the google scholar 
databases to find relevant papers. Papers with a focus outside 
sub-Saharan Africa or falciparum malaria were excluded from 
this review. 
II. MALARIA LIFE CYCLE & DISTRIBUTION 
The malaria life cycle is summarized in Figure 1. It 
typically begins when an infected female Anopheles mosquito 
takes a blood meal injecting sporozoites into the human 
bloodstream. These sporozoites travel to the liver, infecting 
hepatocytes to initiate the pre-erythrocytic phase. About 2 
weeks after, the hepatocytes rupture, releasing merozoites 
which go on to infect erythrocytes, initiating the erythrocytic 
phase of the infection which is responsible for the symptoms 
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	observed during malaria infection. This phase is also marked 
by the breakdown of haemoglobin into an insoluble malaria 
pigment of diagnostic importance called haemozoin. 
Merozoites become ring-like trophozoites, which form the 
basis for malaria diagnosis via microscopy. Subsequently, 
trophozoites divide repetitively to give schizonts which go on 
to develop into merozoites. The new merozoites burst out of 
the erythrocytes and infect other erythrocytes. Some 
merozoites, however develop into male and female 
gametocytes which lay dormant until picked up by a mosquito 
during a blood meal. The gametocytes fuse to form a zygote in 
the stomach of the insect vector after which the zygote 
develops into sporozoites which travel to the salivary gland 
from where they are injected into a human during the next 
blood meal starting the cycle again[4]. 
Malaria symptoms include fever, headache, chills and 
vomiting and in severe cases severe anaemia, respiratory 
distress in relation to metabolic acidosis, or cerebral 
malaria[5]. 
Malaria is currently endemic in most of sub-Saharan 
Africa (Fig. 1).There were 214 million cases of malaria and 
438 000 deaths globally with about 90% of all global cases 
occurring in the sub-Saharan region[3]. Of particular risk are 
children and pregnant women who suffer the most from the 
scourge of malaria. 
 
Figure 1: Life cycle of malaria (right), P. falciparum 
incidence in 2015 [6] 
III. MALARIA DIAGNOSTIC TARGETS 
Malaria diagnosis has been predominantly invasive, 
utilizing whole blood as its primary diagnostic material. 
Recent efforts, however have been given to the application 
other non-invasive materials such as saliva and urine as 
diagnostic materials in malaria diagnosis[7]–[10].Malaria 
diagnosis targets whole cells, such as infected Red blood cells 
(iRBCs) and leukocytes that have ingested parasites or 
detectable analytes such as parasite antigens, haemozoin 
crystals and nucleic acids. These targets have effective thus far 
in malaria diagnosis but not without their individual 
limitations. The ability and accuracy at which these targets are 
detected is dependent on the technology used and such factors 
as reagents, operator proficiency, sample quality and volume. 
Whole cell targets are especially useful as they give current 
information on the state of the parasite in the human body as 
such, they inform treatment and intervention decisions.  
Antigenic targets of malaria diagnosis include the 
Plasmodium falciparum histidine rich protein-II (HRPII), 
lactate dehydrogenase(pLDH) and aldolase. Aldolase is not 
expressed byP.falciparumas such it won’t be considered here. 
HRPII is a water soluble protein antigen expressed by 
P.falciparum trophozoites and localized in several cell 
compartments. The parasite releases a substantial amount of 
the protein into its host’s blood stream making it detectable in 
blood stream[11], [12], cerebrospinal fluid and urine[13]. 
HRPII however persists in the blood stream for up to two 
weeks[14] after parasite must have been cleared greatly 
limiting its diagnostic efficacy as a diagnostic target. This 
persistence has the implication of contributing to the over 
diagnosis and subsequent over treatment of malaria[15], [16]. 
pLDH isis the last enzyme in the glycolytic pathway essential 
for ATP generation. As opposed to HRPII, the amount of 
pLDH in the blood stream reduces as parasites clear from the 
blood stream as such it can be used to monitor treatment 
outcome[17].  
The most suitable diagnostic targets, however would be 
one that accurately tells the current condition of infection viz-
a-viz parasite biomass and species identification 
IV. CURRENT METHODS IN MALARIA 
DIAGNOSIS 
A. ClinicalDiagnosis 
Clinical diagnosis, also known as presumptive diagnosis, 
is the most practiced method of diagnosing malaria as it is 
very cheap and rapid[18]. It is based on the signs and 
symptoms presented by the patient. These signs and symptoms 
are often non-specific and include fever, headache, dizziness, 
cold, nausea, pruritus and anorexia [19]. Clinical diagnosis 
however possess many problems due to the overlap of malaria 
symptoms with those of other common infections found in 
endemic regions such as bacterial infections. This overlap of 
symptoms with other diseases greatly reduces the specificity 
of clinical diagnosis ergo contributing to the over diagnosis 
and over treatment of malaria as shown in various studies with 
one reporting as high as 83% over diagnosis and over 
treatment of malaria in children in the age group of 1-5 years 
of age[20], [21] 
Clinical diagnosis is most useful in areas where there is no 
laboratory support which is often the case in many areas in 
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	sub-Saharan Africa, it is especially useful, and has been 
recommended by the integrated child management 
initiative(IMCI), in treating children, 5 years and below, in 
these areas as malaria infections can quickly become fatal for 
this age group[19], [21]–[23]. 
The sensitivity of clinical diagnosis is determined by 
factors such as endemicity, season and age group with 
accuracy of clinical diagnosis increasing with prevalence and 
endemicity[19], [21].  
The combination of clinical diagnosis with other parasite 
based methods greatly increases the accuracy of malaria 
diagnosis. 
B. Microscopy 
Microscopic examination of Giemsa-stained blood 
smears remains gold standard for the diagnosis of 
malaria.Diagnosis is done by the examination of Giemsa 
stained thin and/or thick blood smear. When performed under 
optimal conditions by a competent microscopist, microscopy 
can detect as low as 5 iRBCs, however its sensitivity can go as 
low as 200iRBCs when conditions are not optimal [24], [25].  
Microscopic examination of blood smears allows for the 
diagnosis of infection in symptomatic and asymptomatic 
persons depending on the skill of the microscopist, 
parasitemia and the number of high powered fields 
observed[26], [27]. It also has the advantage being both 
qualitative (species, stage identification) and quantitative 
hence it’s preferred use in the monitoring of patient response 
to treatment. Microscopy, however falls short in that it 
requires expertise for accurate results, maintenance costs, need 
for constant supply of electricity and others as summarized in 
table 1.Sampling preparation also greatly affects the 
sensitivity of this test as the quality of the film, duration of 
staining and quality of stain affect the ability to visualize the 
different stages of the parasite [18]. 
Recent advances in technology have given rise to new 
ways of manipulating blood in a bid to concentrate cells 
before analyses. The exposure of blood samples to a magnetic 
fields helps concentrate iRBC as a result of the presence of 
haemozoin[28], [29]. This increases the sensitivity of the test 
by as much as 100 fold. Other methods to increase sensitivity 
include the centrifugation of heparinized blood to concentrate 
the different stages of parasite growth before making a 
film[30] however, its application in Africa is not well 
documented. 
The advent of power packs and solar batteries have made 
microscopy more field deployable hence increasing its 
efficacy in resource poor areas. Nonetheless, there is still a 
dearth of experienced mciroscopists in the sub-Saharan 
African region making microscopy a less effective method in 
these parts [31]. 
 
 
C. ImmunochromatographicRapidDiagnosticTests 
The Rapid Diagnostic Test (RDT) is a very effective tool 
in malaria diagnosis and forms the mainstay of diagnosis in 
many resource poor areas where there is no access to a 
laboratory. It is especially useful as it requires no electricity, 
infrastructure, minimal sample preparation, technical expertise 
and interpretation of results is relatively easy.   
The RDT detects malaria antigens in 5-15 µL of blood 
using monoclonal antibodies, impregnated on a test strip, 
specific for the targeted antigens, in an 
immunochromatographic assay. Test results are interpreted by 
the absence or presence of a coloured line on the strip and can 
be obtained in 5-20mins.RDTs detects three plasmodial 
antigens; P.falciparum histidine rich protein II (PfHRPII), 
Plasmodium lactate dehydrogenase (pLDH) and aldolase [17], 
[32]. Most RDT products incorporate two of these three 
antigens in a bid to distinguish falciparum from non-
falciparum infections.  
HRPII antigen is specific for P.falciparum and is a major 
constituent of RDTs in sub-Saharan Africa, it however has the 
shortcoming of persisting for up to 2 weeks after parasite must 
have cleared from the blood stream as such it is not effective 
in monitoring treatment[33], [34]. There have been reports of 
false negatives from HRPIIRDT kits as a result of a mutated 
or deleted HRPII gene [35]. It is recommended that regions 
with more than 10%  prevalence  of HRPII deletion should 
seek alternatives such as microscopy for the diagnosis 
ofP.falciparum malaria[34]. The presence of the rheumatoid 
factor has been shown to give false negative results due to a 
cross reactivity between the factor and HRPII[36], [37]. These 
issues greatly undermine the suitability of HRPII as an ideal 
antigen for the diagnosis of malaria as such RDTs containing 
just HRPII are not advisable for use.pLDH on the other hand 
is highly effective for monitoring treatment outcomes as it 
reflects the current status of parasites in the blood stream [17], 
[38]. pLDH is however not specific to P.falciparum hence its 
combination with HRPII on RDT kits. 
 RDTs have a detection limit as low as 200-2000 
iRBCs/µL[32] depending on the quality of the RDT. The 
sensitivity of RDTs are affected by such factors as storage 
conditions, temperature, and time of assay.One pertinent issue 
militating against the effectiveness of RDTs in sub-Saharan 
Africa is compliance to manufacturer’s instructions and to 
results. A meta-analysis of health workers compliance showed 
that compliance to negative results was low contributing to 
over treatment of malaria [39] 
RDTs for sub-Saharan Africa should be able to withstand 
the conditions found therein. RDTs nonetheless have the 
unique advantage of being field deployable and is especially 
effective in resource poor regions.   
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D. NucleicAcidTechniques 
Tests that target nucleic acids have proven to be one of 
the most specific and sensitive methods with the ability to 
detect parasitemia of 0.005 iRBC/µL [34]. They especially 
come in handy in detecting sub-microscopic infections which 
greatly threaten the elimination strategies that abound. Nucleic 
acid techniques are not yet field deployable as they are 
expensive, require expert personnel and specialized equipment 
as such, their use is limited to clinical research in population 
diversity studies[40] and monitoring of drug resistance[41]. 
Nucleic acid techniques target gene sequences such as 
the 18S ribosomal RNA gene sequences[42], 
P.falciparumstevor multigene family[43], mitochondrial 
DNA, and telomere-associated repetitive element-2[44]. 
Nucleic acid techniques include the Polymerase Chain 
Reaction and its various methods (real time PCR. Nested 
PCR) which use specific primers to make many copies of a 
small amount of template DNA, followed by post-PCR 
methods such as gel electrophoresis. The PCR has the 
advantages of being able to process many samples at once. 
Another nucleic acid technique is the Loop-mediated 
isothermal amplification (LAMP) technique. This technique 
has the potential to make nucleic acid strategies field 
deployable, as it requires lesser instrumentation than PCR and 
is easy to use. LAMP in contrast to PCR is an isothermal 
technique requiring a constant temperature for amplification. 
The amount of DNA produced in LAMP rivals that of PCR as 
LAMP using two to three sets of primers. Amplification is 
detected by turbidimetry due to an increasing quantity of 
magnesium pyrophosphate and as such can be followed in real 
time[45]. Some studies have reported the technique’s ability to 
detect SMI and sensitivities that surpass that of RDT and rival 
that found in PCR[45]–[47]. LAMP is easy, sensitive and 
cheaper than PCR, it however has the downside of the need 
for cold storage of reagents [18]. 
V. PROSPECTSINMALARIADIAGNOSIS 
Recent efforts in malaria diagnosis have been targeted 
towards utilizing other non-invasive diagnostic materials in a 
bid to making testing procedure less painful for most. 
Saliva[7], [8], [48] and urine[9], [13] have been assessed as 
diagnostic material with promising results reported thus far.  
A cheap urine based RDT with the ability to deliver 
results in 25 minutes, is currently undergoing evaluation and 
has shown positive reports with a reported limit of detection 
of 125parasites/µL[13] which is well within the range 
recommended by the WHO [32]. If successful, this new tool 
could finally usher in the era of non-invasive diagnosis of 
malaria. Some studies have also shown the detection of 
parasite DNA in saliva and urine howbeit in smaller quantities 
than those found in the blood[9]. They have however be 
shown to be suitable alternatives to blood where blood 
samples are not available [49]–[51]. 
TABLE 1: Summary of currently used diagnostic techniques 
 Advantages Disadvantages 
Clinical 
Diagnosis 
• Useful in resource poor 
areas 
• Particularly useful in 
preventing infant mortality 
in resource poor regions  
• Sensitivity depends on 
endemicity 
• Leads to over diagnosis 
and subsequent over 
treatment. 
Microscopy • Low Tech, simple and 
inexpensive 
• Field Deployable 
• Identifies parasite itself 
• Useful in monitoring 
treatment outcome 
• Requires expertise 
• Labour intensive 
• Low throughput 
• Rigorous sample 
preparation 
• Requires maintenance  
RDT • Fielddeployable 
• Easy to use 
• Requires no expertise 
• Can detect P.falciparum 
• Zero to minimal sample 
preparation required.  
• Quality control is 
necessary and expensive 
• Environmental condition 
sensitive  
• Antigen can persist 
beyond infection 
• Can’t be used to monitor 
treatment outcome 
Nucleic Acid 
Techniques 
• Highly sensitive 
• Ability to detect SMI 
• Can be used to investigate 
population diversity and 
distinguish between new 
and recrudescent 
infections 
• High throughput 
• Time consuming 
• Expensive 
• Highly skilled personnel 
required 
• Requires provisions to 
avoid cross 
contamination 
• Generally not field 
deployable  
 
Other strategies seek to exploit the electromagnetic and 
physical properties of haemozoin crystals formed during the 
malaria life cycle [28], [52], [53]. Haemozoin based detection 
strategies have the added advantage of giving adequate 
diagnosis during sequestration of parasites. They may 
however not be field deployable as some strategies do not 
detect haemozoin in early ring stage parasites [54] while most 
other techniques require specialized equipment and personnel. 
Another emerging diagnostic tool are the aptamers. 
Aptamers are single-stranded oligonucleotides made in-vitro 
which possess a specific three-dimensional structure 
depending on its sequence [55]. Aptamers interact specifically 
with their targets by binding to them and altering their 
activity. Aptamers targeting pLDH have been designed and 
tested with promising results[56], [57]. It is expected that this 
technology will be perfected and field deployed in the nearest 
future.  
VI. CONCLUSION 
The conventional microscopic examination of blood films 
remain the gold standard as it is cheap and offers sensitivity 
unrivalled by any other field deployable method.RDTs are 
convenient but could lead to over diagnosis and over 
treatment. Nucleic acid techniques offer the best sensitivities, 
they are however expensive, out of reach to most and are 
limited to clinical research.Getting to zero would require 
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	diagnostic tools that are non-invasivehighly sensitive, robust 
and suited to the conditions found in the endemic regions.  
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